pantoprazole has been researched along with Cutaneous T-Cell Lymphoma in 1 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tröger, U | 1 |
| Stötzel, B | 1 |
| Martens-Lobenhoffer, J | 1 |
| Gollnick, H | 1 |
| Meyer, FP | 1 |
1 other study available for pantoprazole and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Benzimidazoles; Dermatologic Agents; Dru | 2002 |